critical host factor, IL-28B

StephenW

The discovery of critical host factor, IL-28B, associated with response to HCV treatment; Mizokami M; Journal of Gastroenterology and Hepatology (Dec 2011)
Chronic hepatitis C affects 2.2 - 3% of the world population (130 million - 170 million). Pegylated interferon-alpha (PEG-IFN-α) in combination with ribavirin (RBV), the approved and standard therapy, leads to viral eradication in about 50% of treated patients. In 2009, genome-wide association studies (GWAS) identified host genetic variation to be critical for predicting treatment response and spontaneous clearance in patients infected with hepatitis C virus (HCV). A correlated set of polymorphisms in the region of the interleukin-28B (IL-28B) gene on chromosome 19, coding for interferon (IFN)-λ3 were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with PEG-IFN-α and RBV. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. In addition, prediction of viral response to PEG-IFN-α and RBV therapy of patients with recurrent HCV infection after orthotopic liver transplantation depends on the IL-28B genotype of both recipient and donor tissues. Diagnosis of a patient's IL-28B genotype is likely to aid in clinical decision making with standard-of-care regimens. Future studies will investigate the possibility of individualizing treatment duration and novel regimens according to IL-28B genotype. As GWAS yield unexpected data, this approach could lead to the development of novel drug therapy, such as already appears promising with IFN- λ. In this Okuda lecture, I present current understanding in regard to the relationship between host variations and clinical outcome of hepatitis C.

StephenW

关键主机因子的发现，IL- 28B，HCV治疗;
Mizokami中号;胃肠病学和肝病学杂志（2011年12月）

   
慢性丙型肝炎的影响2.2 - 3％的世界人口（130万 - 170万）。聚乙二醇α-干扰素（PEG IFN -α）与病毒唑（利巴韦林），核准和标准疗法相结合，导致病毒根除治疗的患者约50％。 2009年，全基因组关联研究（GWAS）确定主机的遗传变异预测与丙型肝炎病毒（HCV）感染患者的治疗反应和自发清除的关键。一个地区的白细胞介素- 28B（IL- 28B）19号染色体上的基因多态性，编码干扰素（IFN）-λ3的相关设置相关的基因1型丙型肝炎病毒（HCV）的间隙，在治疗的患者的PEG IFN-α和利巴韦林。随后，同样的多态性与未经治疗的患者自发清除HCV的。此外，PEG IFN -α和利巴韦林治疗原位肝移植术后复发性丙型肝炎病毒感染的患者的病毒反应的预测取决于受援国和捐助国组织的IL- 28B基因型。对患者的IL- 28B基因型的诊断是可能的援助标准的护理方案，在临床决策的。未来的研究将调查的个体化治疗的时间长短和新颖的方案，根据IL- 28B基因型的可能性。随着GWAS的产生意想不到的数据，这种做法可能导致发展新的药物治疗，如已经出现与干扰素-λ的前途。在此

讲座此，我
介绍
主机的变化和丙型肝炎的临床结果之间的关系方面，在目前的了解.